Retrospective study of teicoplanin loading regimen that rapidly achieves target 15-30 μg/mL serum trough

Hideo Kato1, Yukihiro Hamada1, Mao Hagihara1

  • 1Department of Infection Control and Prevention, Aichi Medical University School of Medicine, Japan; Department of Pharmacy, Aichi Medical University School of Medicine, Japan.

Abstract

Insights

A higher teicoplanin loading dose of 35-40 mg/kg for two days is recommended. This regimen increases the likelihood of achieving therapeutic teicoplanin concentrations and improving patient outcomes in clinical practice.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Clinical Pharmacy

Background:

  • Teicoplanin is an antibiotic used to treat serious bacterial infections.
  • Determining the optimal loading dose for teicoplanin is crucial for achieving therapeutic concentrations and improving efficacy.
  • Previous studies have not definitively established the ideal loading dose regimen.

Purpose of the Study:

  • To evaluate the probability of achieving target teicoplanin concentrations (15-30 μg/mL) within three days of therapy initiation.
  • To compare the clinical efficacy and safety of different teicoplanin loading dose regimens.
  • To identify the optimal loading dose for early therapeutic success.

Main Methods:

  • A retrospective study involving 42 patients treated with teicoplanin.
  • Patients were divided into three groups based on their loading dose: 40 mg/kg (Group 1), 35 mg/kg (Group 2), and 30 mg/kg (Group 3), all administered for two days.
  • Outcomes measured included the proportion of patients achieving target teicoplanin concentrations, clinical efficacy, and incidence of hepatotoxicity and nephrotoxicity.

Main Results:

  • Group 1 (40 mg/kg) achieved 100% target concentration, compared to 57.9% in Group 2 (35 mg/kg) and 38.9% in Group 3 (30 mg/kg) (p=0.05).
  • No significant differences in hepatotoxicity or nephrotoxicity were observed among the groups.
  • While overall clinical efficacy was similar, Groups 1 and 2 showed significantly lower CRP levels 4-7 days post-therapy compared to Group 3.

Conclusions:

  • A teicoplanin loading dose of 35-40 mg/kg for two days is recommended for achieving target concentrations earlier.
  • This higher loading dose regimen may contribute to improved infection management.
  • The safety profile of the higher loading doses was comparable to the standard regimen.

Related Concept Videos

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
317
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
334
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
761
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
346
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
324
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
254